Braftovi (Encorafenib)

Encorafenib is a medicine used to treat melanoma, colon cancer and a type of lung cancer that have a change in a gene called BRAF. It is taken as a capsule by mouth, along with other cancer medicines. It works by blocking a faulty protein that tells the cancer cells to grow.

Brand names:Braftovi
Medication

What people taking Braftovi (Encorafenib) report

Every report comes from a Lived member, sent anonymously.

Have you tried Braftovi (Encorafenib) for Melanoma?

NameHow it went

About Braftovi (Encorafenib)

What It's For

Encorafenib, sold as Braftovi, is a targeted cancer medicine for three cancers that carry a specific change in the BRAF gene: melanoma, colorectal cancer and non-small cell lung cancer (NSCLC), the most common type of lung cancer. It is used only after a test confirms the BRAF V600E mutation, or in melanoma either V600E or V600K. The test is usually done on tumor tissue; for colorectal and lung cancer a blood sample can be tested first, with tissue checked if the blood test finds nothing. Encorafenib is always part of a combination. For melanoma that has spread or cannot be removed with surgery, and for adults with NSCLC that has spread, it is paired with binimetinib (Mektovi), another targeted pill. For adults with colorectal cancer that has spread, it is combined with cetuximab (Erbitux), an antibody given by IV infusion. That can be with standard fluorouracil-based chemotherapy, including as a first treatment for advanced disease, or with cetuximab alone after earlier treatment has stopped working. It is not used for these cancers when the tumor has a normal BRAF gene, because it does not help them and could encourage their growth.

How It Works

BRAF is a protein that works like a switch in a chain of signals telling cells when to grow and divide. The V600 mutation locks that switch in the on position, so cancer cells receive a constant signal to multiply. Encorafenib belongs to a group of drugs called kinase inhibitors. It blocks the overactive BRAF protein and turns that signal down, which can shrink tumors or slow their growth. Cancer cells often find a way around a single blocked step, which is why encorafenib is paired with a second drug. Binimetinib blocks MEK, the next link in the same chain; in laboratory studies the pair worked better than either drug alone and delayed resistance. Colorectal tumors tend to restart the signal through a surface receptor called EGFR (epidermal growth factor receptor), so cetuximab, which blocks EGFR, is added to close that route. In cells without the BRAF mutation, drugs like encorafenib can paradoxically switch the growth signal on, which is why the test matters before starting.

Dosage & Administration

Braftovi comes as 75 mg capsules taken by mouth once a day, with or without food. The starting dose depends on the cancer: six capsules (450 mg) for melanoma and lung cancer, alongside binimetinib, and four capsules (300 mg) for colorectal cancer, alongside cetuximab infusions and, when used, chemotherapy given at the clinic every two weeks. Treatment usually continues for as long as it keeps the cancer under control and side effects remain manageable. The oncology team often lowers or pauses the dose to manage side effects, and if binimetinib or cetuximab is stopped, the encorafenib dose may need to change or stop as well. Follow the current plan rather than adjusting on your own. If you miss a dose, take it when you remember unless your next dose is less than 12 hours away; in that case skip it and take the next dose at the usual time. If you vomit after a dose, do not take an extra one. Avoid grapefruit and grapefruit juice, which raise the amount of drug in the body. Keep the capsules in their original bottle with the drying packet inside and the cap tightly closed, because they are sensitive to moisture.

Side Effects

Side effects depend partly on the partner drugs. With binimetinib, the most common are tiredness, nausea, vomiting, belly pain and joint pain; people with lung cancer also often notice diarrhea, blurred vision and shortness of breath. With cetuximab, an acne-like rash, diarrhea, tiredness, nausea and loss of appetite are common, and adding chemotherapy brings its own effects, such as numbness or tingling in the hands and feet, hair loss and fever. Many of these can be eased with supportive medicines or dose changes. New skin cancers, mainly squamous cell and basal cell skin cancers, and occasionally a new melanoma, can develop during treatment. Tell your care team promptly about a new wart, a sore or reddish bump that bleeds or does not heal, or a mole that changes in size or color. Such spots are usually removed and examined. Bleeding is more likely than usual, most often from the nose or bowel, and serious bleeding in the stomach or brain has occurred. Get medical help right away for signs of serious bleeding: vomiting blood or material that looks like coffee grounds, red or black tarry stools, coughing up blood, or headache, dizziness or weakness that could signal bleeding in the brain. Other effects to report promptly include vision changes such as blurring, colored dots, halos, or eye pain or redness, which can signal inflammation inside the eye (uveitis); feeling faint or a racing or irregular heartbeat, which can reflect a change in the heart's rhythm; and, especially with binimetinib, shortness of breath or swelling in the legs, which can mean the heart is pumping less strongly. Yellowing of the skin or eyes or dark, tea-colored urine can signal liver strain.

Interactions & Warnings

Encorafenib interacts with many medicines, so the oncology team and pharmacist need a full list, including over-the-counter drugs and herbal supplements. Medicines that slow the liver enzyme CYP3A4, such as the antifungal posaconazole or diltiazem (a heart and blood pressure medicine), raise encorafenib levels and are usually avoided or require a lower dose; grapefruit has the same effect. Medicines that strongly speed up that enzyme can make encorafenib less effective. Encorafenib itself speeds up the same enzyme, so it can weaken other medicines broken down that way. Medicines that also affect the heart's rhythm are generally avoided, and low potassium or magnesium is corrected before and during treatment. Encorafenib can harm a developing baby, and it makes hormonal birth control such as pills, injections and patches less reliable. Women who could become pregnant need a pregnancy test before starting and should use an effective nonhormonal method during treatment and for 2 weeks after the last dose. Breastfeeding is not recommended over the same period. In men, encorafenib may affect fertility. The safety of encorafenib with binimetinib has not been established in people whose heart pumping strength is already reduced, so existing heart problems, long QT syndrome (an inherited heart rhythm disorder), bleeding problems, eye disease and liver or kidney problems should be discussed before starting.

What to Expect

How well encorafenib works, and for how long, varies from person to person. In the main melanoma trial, people taking it with binimetinib went a median of about 15 months before the cancer grew, compared with about 7 months on an older BRAF drug, vemurafenib, and lived a median of about 34 months versus 17. In colorectal cancer treated first with encorafenib, cetuximab and chemotherapy, median survival was about 30 months compared with about 15 months on standard chemotherapy. These are averages from trials; many tumors eventually find a way to grow again, and the team then discusses next options. Treatment brings regular check-ins. Expect blood tests for liver function, often monthly; heart scans (an echocardiogram, which is an ultrasound, or a MUGA scan, a nuclear imaging test) before starting, after a month and every few months when binimetinib is part of the plan; heart rhythm tests (ECGs) and electrolyte checks; eye checks at visits and exams for any vision change; and skin checks before treatment, every 2 months during it and for up to 6 months after it ends. Scans of the cancer track whether the treatment is still working.

Questions to Ask Your Doctor

  1. 1.Which BRAF mutation does my tumor have, and how was it confirmed?
  2. 2.Why is this combination recommended for me compared with other options, such as immunotherapy or a different targeted pair?
  3. 3.How will we know if it is working, and what is the plan if the cancer starts growing again?
  4. 4.Which of my current medicines or supplements could interact with encorafenib, and what birth control should I use?
  5. 5.Which side effects should I call about the same day, and who do I contact after hours?

Last reviewed • Oct 2026

Educational content, not medical advice.